Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2016

01-06-2016 | original report

Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer

Authors: Mathilde Foedermayr, Miriam Sebesta, Margaretha Rudas, Anna S. Berghoff, Regina Promberger, Matthias Preusser, Peter Dubsky, Michael Gnant, Guenther G. Steger, Ansgar Weltermann, Christoph C. Zielinski, Otto Zach, Rupert Bartsch

Published in: memo - Magazine of European Medical Oncology | Issue 2/2016

Login to get access

Abstract

Despite recent improvements, triple-negative breast cancer (TNBC) remains a breast cancer subtype with poor prognosis. TP53 mutations are commonly associated with TNBC, suggesting a role in breast cancer carcinogenesis. In addition to mutations, several reports focused on TP53 polymorphisms and their association with breast cancer risk and outcome. TP53 codon Pro72Arg polymorphism may predict response to anti-cancer therapy as Pro72 is apparently less effective in the induction of apoptosis.
Here, we investigated a potential association of TP53 mutations with TP53 codon 72 polymorphism and clinical outcome in a homogeneous cohort of TNBC patients.
DNA isolated from formalin-fixed paraffin-embedded tissue of 35 consecutive TNBC patients was investigated for TP53 mutation and TP53 codon 72 polymorphic status by Sanger sequencing.
The kind of TP53 mutations were associated with particular polymorphic Pro72Arg genotypes. Frameshift mutations were significantly correlated with Pro/Pro carriers, nonsense mutations showed a trend for Pro/Arg carriers. Despite this observation no association with clinical outcome was observed.
Further studies with larger and more homogeneous cohorts are warranted in order to elucidate a potential association of TP53 Pro72Arg polymorphism and particular TP53 mutations with TNBC carcinogenesis and outcome.
Literature
1.
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–2502.CrossRefPubMed
2.
Curigliano G, Goldhirsch A. The triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monographs. 2011;43:108–110.CrossRef
3.
Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumour phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622–629.CrossRefPubMed
4.
Walerych D, Napoli M, Collavin L, Sal G Del. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012;33(11):2007–2017.CrossRefPubMedPubMedCentral
5.
6.
Li T, Kon N, Jiang L, et al. Tumour suppression in the absence of p53-mediated cell cycle arrest, apoptosis, and senescence. Cell. 2012;149(6):1269–1283.CrossRefPubMedPubMedCentral
7.
Själander A, Birgander R, Kivelä A, Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered. 1995;45(3):144–149.CrossRefPubMed
8.
Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004;23(19):3328–3337.CrossRefPubMed
9.
Beckman G, Birgander R, Själander A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered. 1994;44(5):266–270.CrossRefPubMed
10.
Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):876–884.CrossRefPubMed
11.
Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA. 1991;88(22):10124–10128.CrossRefPubMedPubMedCentral
12.
Själander A, Birgander R, Hallmans G, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1999;17(6):1313–1316.CrossRef
13.
Godai TI, Suda T, Sugano N, et al. Identification of colorectal cancer patients with tumours carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5‑fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer. 2009;2(9):420.CrossRef
14.
Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008.CrossRefPubMedPubMedCentral
15.
Proestling K, Hebar A, Pruckner N, Marton E, Vinatzer U, Schreiber M. The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoural expression of BAX and p21, and increased breast cancer risk. PloS One. 2012;7(10):e47325.CrossRefPubMedPubMedCentral
16.
Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011;39(Database Issue):D945–D950.CrossRefPubMed
17.
Weston A, Godbold JH. Polymorphisms of H‑ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect. 1997;4:919–926.CrossRef
18.
Foedermayr M, Sebesta M, Rudas M, et al. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2014;73(4):771–778.CrossRefPubMed
19.
Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumour suppressor gene: important milestones at the various steps of tumourigenesis. Genes Cancer. 2011;2(4):466–474.CrossRefPubMedPubMedCentral
20.
Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91(2):355–358.PubMedPubMedCentral
21.
Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006;8(4):R38.CrossRefPubMedPubMedCentral
22.
Olivier M, Langerød A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006;12(4):1157–1167.CrossRefPubMed
23.
Zhuo W, Zhang Y, Xiang Z, Cai L, Chen Z. Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. J Exp Clin Cancer Res. 2009;28:115.CrossRefPubMedPubMedCentral
24.
He XF, Su J, Zhang Y, et al. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat. 2011;130(2):517–529.CrossRefPubMed
25.
Langerød A, Bukholm IR, Bregård A, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1684–1688.PubMed
26.
Dumont P, I‑Ju Leu J, Pietra AC Della, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–365.CrossRefPubMed
27.
Wegman PP, Marcus NJ, Malakkaran BP, Wingren S. Biological significance of allele specific loss of the p53 gene in breast carcinomas. Breast Cancer Res Treat. 2009;18(1):15–20.CrossRef
Metadata
Title
Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer
Authors
Mathilde Foedermayr
Miriam Sebesta
Margaretha Rudas
Anna S. Berghoff
Regina Promberger
Matthias Preusser
Peter Dubsky
Michael Gnant
Guenther G. Steger
Ansgar Weltermann
Christoph C. Zielinski
Otto Zach
Rupert Bartsch
Publication date
01-06-2016
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2016
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0261-9

Other articles of this Issue 2/2016

memo - Magazine of European Medical Oncology 2/2016 Go to the issue

editorial

memo—new frontiers to be reached

case report

Intravascular large B‑cell lymphoma

case report

Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option

case report

Endometrial cancer treated with levonorgestrel-releasing intrauterine device for almost three years in an elderly woman with comorbidity

short review

CDK4/6 inhibition in luminal breast cancer

comment

Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits